. 2019 Sep 10;9:12937. doi: 10.1038/s41598-019-49419-z

Table 2.

G-CSF and GM-CSF concentrations in sputum and serum.

	Sputum	Serum
G-CSF	0.22** (0.13–0.32)	0.21** (0.05–0.36)	0.15 (0.00–0.36)	0.07 (0.02–0.12)	0.04 (0.01–0.09)	0.07 (0.03–0.17)
GM-CSF	0.005 (0.002–0.012)	0.008 (0.003–0.012)	0.004 (0.002–0.014)	0.009 (0.007–0.014)	0.005 (0.003–0.01)	0.01 (0.006–0.01)

Sputum

Serum

Stable

Pre-therapy

Post-therapy

Stable

Pre-therapy

Post-therapy

G-CSF

0.22**

(0.13–0.32)

0.21**

(0.05–0.36)

0.15

(0.00–0.36)

0.07

(0.02–0.12)

0.04

(0.01–0.09)

0.07

(0.03–0.17)

GM-CSF

0.005

(0.002–0.012)

0.008

(0.003–0.012)

0.004

(0.002–0.014)

0.009

(0.007–0.014)

0.005

(0.003–0.01)

0.01

(0.006–0.01)

G-CSF and GM-CSF levels (ng/ml) are reported as median (interquartile range). Kruskall-Wallis (with Dunn’s test as post hoc test) and Mann-Whitney U-test: **sputum G-CSF stable vs. serum G-CSF stable and sputum G-CSF pre-therapy vs serum G-CSF pre-therapy: P < 0.01.